Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06663059 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Adebrelimab Neoadjuvant Treatment for Resectable ESCC: 2 vs 4 Cycles Study

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated October 29, 2024 (before its estimated December 1, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
Observing the efficacy and safety of 2 cycles versus 4 cycles of Adebrelimab combined with chemotherapy as neoadjuvant treatment for patients with resectable locally advanced thoracic esophageal squamous cell carcinoma.
Trial Details
NCT Number NCT06663059
Lead Sponsor Tang-Du Hospital
Conditions
(from sponsor)		 Esophageal Cancer
Related terms Esophageal Neoplasms, Esophageal Squamous Cell Carcinoma
Enrollment 80 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov